Cycle Pharmaceuticals Ltd.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.cyclepharma.com
Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04411940
- Locations
- 🇿🇦
FARMOVS Clinical Research Organisation, Bloemfontein, Free State, South Africa
Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04411953
- Locations
- 🇿🇦
FARMOVS Clinical Research Organisation, Bloemfontein, Free State, South Africa
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Phase 1
Completed
- Conditions
- Anti-PsychoticControl Manifestations of the Manic Type of Mani-depressive IllnessControl Nausea and VomitingAdjunct in the Treatment of TetanusRelief of Intractable HiccupsManagement of Manifestations of Psychotic DisordersAcute Intermittent PorphyriaTreatment of SchizophreniaRelief of Restlessness and Apprehension Before Surgery
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02943213
- Locations
- 🇿🇦
Farmovs Parexel, Bloemfontein, Kampuslaan Suid, South Africa
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02750332
- Locations
- 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa
Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
Phase 1
Completed
- Conditions
- Hereditary Tyrosinemia, Type I
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02750345
- Locations
- 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
Phase 1
Completed
- Conditions
- Hereditary Tyrosinemia, Type I
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Cycle Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02750709
- Locations
- 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa
© Copyright 2025. All Rights Reserved by MedPath